Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Invesco Ltd.

Invesco Ltd. grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 299,279 shares of the company's stock after buying an additional 14,747 shares during the quarter. Invesco Ltd. owned 0.62% of Mirum Pharmaceuticals worth $12,375,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Barclays PLC grew its position in shares of Mirum Pharmaceuticals by 4.6% in the third quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after purchasing an additional 10,824 shares during the period. Geode Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after buying an additional 29,017 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $28,913,000. Hennion & Walsh Asset Management Inc. increased its stake in Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after buying an additional 29,545 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $189,000.

Mirum Pharmaceuticals Trading Up 0.6 %

MIRM stock traded up $0.24 during trading on Friday, reaching $40.71. 75,126 shares of the stock were exchanged, compared to its average volume of 522,274. The business has a 50 day moving average price of $44.36 and a 200-day moving average price of $43.96. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -20.15 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MIRM shares. HC Wainwright lifted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $58.20.

Insider Activity at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,102 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the transaction, the chief executive officer now directly owns 115,920 shares in the company, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jolanda Howe sold 1,064 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $51,306.08. Following the sale, the senior vice president now owns 4,232 shares in the company, valued at $204,067.04. This trade represents a 20.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 105,557 shares of company stock worth $4,726,040. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.